Pharmacyclics

Pharmacyclics, Inc. is an integrated biopharmaceutical company engaged in developing and commercializing therapies for the treatment of cancer and immune-mediated diseases. The Company’s commercial product is IMBRUVICA (ibrutinib), which is an oral, single-agent therapy indicated for the treatment of blood cancer. 
IMBRUVICA (ibrutinib) is a prescription medicine used to treat people with marginal zone lymphoma (MZL) who require a medicine by mouth or injection (systemic therapy) and have received a certain type of prior treatment.

Type
Subsidiary
Parent Company
AbbVie
HQ
Sunnyvale, US
Founded
1991
Pharmacyclics was founded in 1991 and is headquartered in Sunnyvale, US

Pharmacyclics Office Locations

Pharmacyclics has offices in Sunnyvale, South San Francisco, Shanghai and Schaffhausen
Sunnyvale, US (HQ)
999 E Arques Ave
Schaffhausen, CH
36 Mühlentalstrasse
Shanghai, CN
1551 Sichuan N Rd
South San Francisco, US
601 Gateway Blvd

Pharmacyclics Data and Metrics

Pharmacyclics Summary

Founding Date

1991

Investors

Pharmacyclics is a subsidiary of AbbVie

Pharmacyclics Financial Metrics

Pharmacyclics's revenue was reported to be $729.7 m in FY, 2014 which is a 180% increase from the previous period.
Numbers are in $, USDFY, 2013FY, 2014

Revenue

260.2 m729.7 m

Revenue growth, %

180%

Cost of goods sold

Gross profit

689.3 m

Gross profit Margin, %

94%

Operating expense total

158.7 m566.9 m

EBIT

97.9 m122.4 m

EBIT margin, %

38%17%

Interest income

137 k

Pre tax profit

120.2 m

Income tax expense

2.6 m

Net Income

67 m86.1 m
Numbers are in $, USDFY, 2013FY, 2014

Cash

624 m845 m

Accounts Receivable

11 m64.3 m

Inventories

9.3 m20.6 m

Current Assets

740.8 m1 b

PP&E

25.5 m32.5 m

Total Assets

768.8 m1.1 b

Accounts Payable

4 m7.3 m

Current Liabilities

87.6 m194.2 m

Additional Paid-in Capital

844.2 m959.6 m

Retained Earnings

(216.6 m)(130.5 m)
Numbers are in $, USDFY, 2013FY, 2014

Net Income

117.5 m117.5 m

Depreciation and Amortization

595 k595 k

Accounts Receivable

Inventories

Accounts Payable

1.6 m1.6 m

Cash From Operating Activities

110.7 m110.7 m

Purchases of PP&E

(2.4 m)(2.4 m)

Cash From Investing Activities

(6.4 m)(6.4 m)

Cash From Financing Activities

5.2 m5.2 m

Income Taxes Paid

980 k980 k

Pharmacyclics Median Salaries

Source: 39 public H-1B filings from Pharmacyclics

Pharmacyclics Online and Social Media Presence

Pharmacyclics Company Life and Culture

You may also be interested in